The value of metabolic imaging to predict tumour response after chemoradiation in locally advanced rectal cancer

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Palma, Pablo ^a   Conde Muíño, Raquel ^a   Rodríguez Fernández, Antonio ^a   Segura Jiménez, Inmaculada ^a   Sánchez Sánchez, Rocío ^a   Martín Cano, Javier ^a   Gómez Río, Manuel ^a   Ferrón, José A ^a   Llamas Elvira, José M ^a  

^a HUVN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; OXALIPLATIN; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; PREDICTION; PREDICTIVE VALUE; RECTUM CANCER; SENSITIVITY AND SPECIFICITY; ADJUVANT CHEMOTHERAPY; CARCINOMA; CLINICAL TRIAL; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECTUM TUMOR; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECTAL NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 78650045272     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-119     Document Type: Article

References (22)

1. Glynne-Jones R, Dunst J, Sebag-Montefiore D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?. Ann Oncol 2006, 17:361-371. 10.1093/annonc/mdj052, 16500912.
2. Habr-Gama A, Perez RO. Non-operative management of rectal cancer after neoadjuvant chemoradiation. Br J Surg 2009, 96:127-127.
3. Neuman HB, Elkin EB, Guillem JG, Paty PB, Weiser MR, Wong WD, Temple LK. Treatment for patients with rectal cancer and a clinical complete response to neoadjuvant therapy: A decision analysis. Dis Colon Rectum 2009, 52:863-871.
4. Kim SH, Lee JM, Hong SH, Kim GH, Lee JY, Han JK, Choi BI. Locally advanced rectal cancer: Added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology 2009, 253:116-125. 10.1148/radiol.2532090027, 19789256.
5. Ruhlmann J, Schomburg A, Bender H. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1998, 40:1195-1204.
6. Llamas-Elvira JM, Rodríguez-Fernández A, Gutiérrez-Sáinz J, Gomez-Rio M, Bellón-Guardia M, Ramos-Font C, Rebollo-Aguirre AC, Cabello-García D, Ferrón Orihuela A. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging 2007, 34:859-867. 10.1007/s00259-006-0274-4, 17195075.
7. Mandard AN, Dalibar DF, Mandard JC. Pathological assessment of tumor regression after preoperative chemotherapy of oesophageal carcinoma: clinico-pathological correlations. Cancer 1994, 73:2680-2686. 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C, 8194005.
8. de Geus-Oei LF, Vriens D, van Laarhoven HWM, van der Graaf WTA, Oyen WJG. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 2009, 50:43-54.
9. Guillem JG, Puig-La Calle J, Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac H, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, Larson S. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000, 43:18-24. 10.1007/BF02237238, 10813118.
10. Calvo FA, Domper M, Matute R, Martínez-Lázaro R, Arranz JA, Desco M, Alvarez E, Carreras JL. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004, 58:528-535. 10.1016/j.ijrobp.2003.09.058, 14751524.
11. Denecke T, Rau B, Hoffmann KT, Hildebrandt B, Ruf J, Gutberlet M, Hünerbein M, Felix R, Wust P, Amthauer M. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?. Eur Radiol 2005, 15:1658-1666. 10.1007/s00330-005-2658-4, 15806369.
12. Capirci C, Rampin L, Erba PA, Galeotti F, Crepaldi G, Banti E, Gava M, Fanti S, Mariani G, Muzzio PC, Rubello D. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 2007, 34:1583-1593. 10.1007/s00259-007-0426-1, 17503039.
13. Melton GB, Lavely WC, Jacene HA, Schulick RD, Choti MA, Wahl RL, Gearhart S. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg 2007, 11:961-969. 10.1007/s11605-007-0170-7, 17541799.
14. Kristiansen C, Loft A, Berthelsen AK, Graff J, Lindebjerg J, Bisgaard C, Jakobsen A. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum 2008, 51:21-25. 10.1007/s10350-007-9095-1, 17975715.
15. Konski A, Li T, Sigurdson E, Cohen SJ, Small W, Spies S, Yu JQ, Wahl A, Stryker S, Meropol NJ. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys 2009, 74:55-59. 10.1016/j.ijrobp.2008.07.050, 2933375, 19004571.
16. de Campos-Lobato LF, Stocchi L, da Luz Moreira A, Kalady MF, Geisler D, Dietz D, Lavery IC, Remzi FH, Fazio VW. Downstaging without complete pathologic response after neoadjuvant treatment improves cancer outcomes for cIII but not cII rectal cancers. Ann Surg Oncol 2010, 17:1758-1766. 10.1245/s10434-010-0924-4, 20131015.
17. Capirci C, Rubello D, Chierichetti F, Crepaldi G, Fanti S, Mandoliti G, Salviato S, Boni G, Rampin L, Polico C, Mariani G. Long-term prognostic value of 18FFDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. AJR 2006, 187:202-208.
18. Guillem JG, Moore HG, Akhurst T, Klimstra DS, Ruo L, Mazumdar M, Minsky BD, Saltz L, Wong WD, Larson S. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining long-term outcomes of rectal cancer. J Am Coll Surg 2004, 199:1-7. 10.1016/j.jamcollsurg.2004.02.024, 15217621.
19. Nakagawa K, Yamashita H, Nakamura N, Igaki H, Tago M, Hosoi Y, Momose T, Ohtomo K, Muto T, Nagawa H. Preoperative radiation response evaluated by 18-fluorodeoxyglucose positron emission tomography predicts survival in locally advanced rectal cancer. Dis Colon Rectum 2008, 51:1055-1060. 10.1007/s10350-008-9243-2, 18449608.
20. Cascini GL, Avallone A, Delrio P, Guida C, Tatangelo F, Marone P, Aloj L, De Martinis F, Comella P, Parisi V, Lastoria S. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 2006, 47:1241-1248.
21. Janssen MH, Ollers MC, Riedl RG, van der Bogaard J, Buijsen J, van Stiphout RGPM, Aerts HJWL, Lambin P, Lammering G. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using 18F-Fuorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiation Oncology 2010, 77:392-399.
22. Akhurst T, Kates TJ, Mazumdar M, Yeung H, Riedel ER, Burt BM, Blumgart L, Jarnagin W, Larson SM, Fong Y. Recent chemotherapy reduces the sensitivity of 18F-fluorodeoxyglucose positron emission tomography in the detection of colorectal metastates. J Clin Oncol 2005, 23:8713-8716. 10.1200/JCO.2005.04.4222, 16314631.